429 related articles for article (PubMed ID: 16140943)
21. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
[TBL] [Abstract][Full Text] [Related]
22. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.
Fiorentino FP; Macaluso M; Miranda F; Montanari M; Russo A; Bagella L; Giordano A
Mol Cancer Res; 2011 Feb; 9(2):225-33. PubMed ID: 21325284
[TBL] [Abstract][Full Text] [Related]
23. Alternative promoters of gene MAGE4a.
De Plaen E; Naerhuyzen B; De Smet C; Szikora JP; Boon T
Genomics; 1997 Mar; 40(2):305-13. PubMed ID: 9119398
[TBL] [Abstract][Full Text] [Related]
24. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
[TBL] [Abstract][Full Text] [Related]
25. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.
Bhan S; Negi SS; Shao C; Glazer CA; Chuang A; Gaykalova DA; Sun W; Sidransky D; Ha PK; Califano JA
Clin Cancer Res; 2011 Jul; 17(13):4267-76. PubMed ID: 21558405
[TBL] [Abstract][Full Text] [Related]
26. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
27. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
28. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
[TBL] [Abstract][Full Text] [Related]
29. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.
De Smet C; Lurquin C; Lethé B; Martelange V; Boon T
Mol Cell Biol; 1999 Nov; 19(11):7327-35. PubMed ID: 10523621
[TBL] [Abstract][Full Text] [Related]
31. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
32. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
33. CTCF and BORIS in genome regulation and cancer.
Marshall AD; Bailey CG; Rasko JE
Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
[TBL] [Abstract][Full Text] [Related]
34. Discovering a binary CTCF code with a little help from BORIS.
Lobanenkov VV; Zentner GE
Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
[TBL] [Abstract][Full Text] [Related]
35. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells.
Law AY; Lai KP; Ip CK; Wong AS; Wagner GF; Wong CK
Exp Cell Res; 2008 May; 314(8):1823-30. PubMed ID: 18394600
[TBL] [Abstract][Full Text] [Related]
37. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.
Dougherty CJ; Ichim TE; Liu L; Reznik G; Min WP; Ghochikyan A; Agadjanyan MG; Reznik BN
Biochem Biophys Res Commun; 2008 May; 370(1):109-12. PubMed ID: 18355444
[TBL] [Abstract][Full Text] [Related]
38. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine.
Liang G; Gonzales FA; Jones PA; Orntoft TF; Thykjaer T
Cancer Res; 2002 Feb; 62(4):961-6. PubMed ID: 11861364
[TBL] [Abstract][Full Text] [Related]
39. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
